
MAC.15 | RxPONDER
NCT01272037
MAC.15
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Status:
Closed to Accrual

III
Phase

Adjuvant
Line of Therapy

Early Cancer
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
Treatment Arms
o Experimental: Arm II (endocrine therapy)
o Experimental: Arm I (chemotherapy and endocrine therapy)